BACKGROUND AND OBJECTIVE: Long-term observational studies may provide additional information about the behaviour of different drugs in the post-marketing period. We present the data of our cohort of relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon beta (IFNbeta). METHODS: We analysed RRMS patients followed for at least 2 years. From 1995, we initiated therapy with IFNbeta. As they became available, patients were allocated to one of the IFNs at standard doses (IFNbeta-1b, IFNbeta-1a i.m. or IFNbeta-1a s.c.). Each patient was included in a follow-up protocol containing demographic and baseline clinical data. RESULTS: Between 1995 and 2004, 382 patients have completed at least 2 years of follow-up. Significant differences at entry were observed. Patients on IFNbeta-1b had a higher disease activity and disability at baseline than those on IFNbeta-1a i.m. or IFNbeta-1a s.c. A significant reduction in the relapse rate was observed for the three drugs (70% for IFNbeta-1b, 64% for IFNbeta-1a i.m. and 74% for IFNbeta-1a s.c.). We observed a sustained progression of disability in 11% of patients on IFNbeta-1b, 17% on IFNbeta-1a i.m. and 19% on IFNbeta-1a s.c.; and at four years of follow-up in 24% of patients on IFNbeta-1b, 23% on IFNbeta-1a i.m. and 35% on IFNbeta-1a s.c. No unexpected major adverse events were observed with any of the drugs. CONCLUSIONS: Interferon beta is safe and well tolerated. The various registered interferon beta drugs provide a comparable efficacy in a large non-selected cohort of RRMS patients.
BACKGROUND AND OBJECTIVE: Long-term observational studies may provide additional information about the behaviour of different drugs in the post-marketing period. We present the data of our cohort of relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon beta (IFNbeta). METHODS: We analysed RRMS patients followed for at least 2 years. From 1995, we initiated therapy with IFNbeta. As they became available, patients were allocated to one of the IFNs at standard doses (IFNbeta-1b, IFNbeta-1a i.m. or IFNbeta-1a s.c.). Each patient was included in a follow-up protocol containing demographic and baseline clinical data. RESULTS: Between 1995 and 2004, 382 patients have completed at least 2 years of follow-up. Significant differences at entry were observed. Patients on IFNbeta-1b had a higher disease activity and disability at baseline than those on IFNbeta-1a i.m. or IFNbeta-1a s.c. A significant reduction in the relapse rate was observed for the three drugs (70% for IFNbeta-1b, 64% for IFNbeta-1a i.m. and 74% for IFNbeta-1a s.c.). We observed a sustained progression of disability in 11% of patients on IFNbeta-1b, 17% on IFNbeta-1a i.m. and 19% on IFNbeta-1a s.c.; and at four years of follow-up in 24% of patients on IFNbeta-1b, 23% on IFNbeta-1a i.m. and 35% on IFNbeta-1a s.c. No unexpected major adverse events were observed with any of the drugs. CONCLUSIONS:Interferon beta is safe and well tolerated. The various registered interferon beta drugs provide a comparable efficacy in a large non-selected cohort of RRMS patients.
Authors: J H Simon; L D Jacobs; M Campion; K Wende; N Simonian; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J J Alam; J S Fischer; D E Goodkin; C V Granger; M Lajaunie; A L Martens-Davidson; M Meyer; J Sheeder; K Choi; A L Scherzinger; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; R H Whitham Journal: Ann Neurol Date: 1998-01 Impact factor: 10.422
Authors: H Panitch; D S Goodin; G Francis; P Chang; P K Coyle; P O'Connor; E Monaghan; D Li; B Weinshenker Journal: Neurology Date: 2002-11-26 Impact factor: 9.910
Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422
Authors: J H Noseworthy; P O'Brien; B J Erickson; D Lee; D Sneve; G C Ebers; G P Rice; A Auty; W J Hader; A Kirk; P Duquette; J Carter; G Francis; L Metz; E Shuster Journal: Neurology Date: 1998-11 Impact factor: 9.910
Authors: Volker Limmroth; Rolf Malessa; Uwe Klaus Zettl; Jürgen Koehler; Gudrun Japp; Peter Haller; Wolfgang Elias; Winfried Obhof; Andrea Viehöver; Uwe Meier; Arne Brosig; Joerg Hasford; Norman Putzki; Gabriele Kalski; Colin Wernsdörfer Journal: J Neurol Date: 2007-02-01 Impact factor: 4.849
Authors: Ray Gani; Gavin Giovannoni; David Bates; Belinda Kemball; Steve Hughes; John Kerrigan Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981